Clinical Trial Update: Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating the efficacy and safety of AZD4831 in heart failure with preserved ejection fraction has completed, and the results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• AZD4831 (AZD4831)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-08-27